Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation.
Ninety patients who underwent cardioversion of persistent atrial fibrillation (AF) were randomized to bisoprolol 5 to 10 mg once daily or carvedilol 12.5 to 25 mg twice daily. Using intention-to-treat analysis, 23 patients (46%) in the bisoprolol group and 17 patients (32%) in the carvedilol group relapsed into AF during the 1 year of total follow-up (p = 0.486). Patients treated with carvedilol had a 14% (hazard ratio 0.86) lower risk of relapse of AF compared with patients in the bisoprolol group, although results were statistically insignificant (p = 0.661) after controlling for patient age, gender, baseline heart rate, and left atrial diameter.
Katritsis
Demosthenes G
DG
Department of Cardiology, Athens Euroclinic, Athens, Greece. dkatritsis@euroclinic.gr
Panagiotakos
Demosthenes B
DB
Karvouni
Evangelia
E
Giazitzoglou
Eleftherios
E
Korovesis
Socrates
S
Paxinos
George
G
Anagnostopoulos
Constantine E
CE
Camm
A John
AJ
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000368:Aged; D001281:Atrial Fibrillation / Q000517:prevention & control*; D017298:Bisoprolol / Q000627:therapeutic use*; D002227:Carbazoles / Q000627:therapeutic use*; D000077261:Carvedilol; D004311:Double-Blind Method; D004554:Electric Countershock; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000627:therapeutic use*; D055502:Secondary Prevention; D013997:Time Factors; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol; D017298:Bisoprolol